10-K: ProMIS Neurosciences 2023 10-K Filing: Focus on Clinical Trials and Pipeline Expansion

ProMIS Neurosciences' 2023 annual report highlights progress in clinical trials for PMN310, along with continued development of its pipeline targeting neurodegenerative diseases.

Summary

• ProMIS Neurosciences is focused on developing antibody therapies and therapeutic vaccines for neurodegenerative diseases, utilizing a patented technology platform.
• The company's lead program, PMN310, is in Phase 1a clinical trials for Alzheimer's disease, with plans for a Phase 1b trial in Alzheimer's patients.
• Other pipeline candidates include PMN267 for ALS and PMN442 for MSA, both in preclinical development.
• The company incurred a net loss of $13.2 million in 2023, with an accumulated deficit of $93.5 million.
• ProMIS is dependent on additional financing to continue operations and achieve its goals.
• The company's technology platform uses computational modeling to identify unique epitopes on misfolded proteins, which are then targeted by therapeutic antibodies.
• The company has a three-layered intellectual property strategy, including computational algorithms, disease-specific epitopes, and composition of matter for antibodies.
• ProMIS plans to out-license the marketing and sales of its products to strategic partners for commercialization.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and pipeline development, the company's financial situation and dependence on future funding raise concerns. The company is also operating in a highly competitive and risky industry.

Positives

• The company has successfully manufactured PMN310 clinical supply under cGMP conditions.
• The company received FDA clearance to initiate a Phase 1a clinical trial of PMN310.
• Preclinical studies of PMN310 have shown promising results in mouse models of Alzheimer's disease.
• The company's vaccine program has shown robust induction of antibodies selective for amyloid oligomers in preclinical studies.
• The company's technology platform has the potential to produce more effective and safer antibodies compared to traditional methods.

Negatives

• The company has incurred losses since inception and anticipates continued losses for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has no product candidates approved for commercial sale and has never generated any revenue from product sales.
• The company is heavily dependent on the successful development, regulatory approval, and commercialization of PMN310 and other product candidates.
• The company faces significant competition in an environment of rapid technological and scientific change.

Risks

• The company's product candidates are still in the early stages of development, and there is significant uncertainty that any such products will actually be developed.
• The company will require additional financing to achieve its goals, and a failure to obtain this necessary capital could force the company to delay, limit, reduce, or terminate its development programs.
• The company relies on third parties to supply components, research, develop, test, and manufacture its product candidates, and the loss of any of these third-party relationships could affect the company's ability to develop and obtain approval of its product candidates.
• The company may not be successful in obtaining or maintaining sufficient intellectual property protection for its product candidates, and other proprietary technologies it develops.
• The company's relationships with customers, healthcare providers, and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations.
• The company faces significant competition in an environment of rapid technological and scientific change, and there is a possibility that its competitors may achieve regulatory approval before the company or develop therapies that are safer or more effective than the company's.
• The company's internal controls over financial reporting may not be effective, which could have a material and adverse effect on its business.
• The company is subject to the continued listing criteria of Nasdaq, and its failure to satisfy these criteria may result in a delisting of its Common Shares.

Future Outlook

The company expects to continue to incur losses for the foreseeable future and will need to obtain substantial additional funding to support its continuing operations and pursue its growth strategy. The company plans to pursue key objectives for 2024, including completing the Phase 1a clinical study with PMN310, preparing for the Phase 1b clinical study with PMN310, and conducting further preclinical studies to support pipeline candidates.

Management Comments

• Management believes its working capital position raises substantial doubt about the Company's ability to continue as a going concern within the next twelve months from the date of the issuance of the consolidated financial statements.
• Management believes that the greater selectivity of PMN310 for AO may result in greater neutralization of this disease-causing species compared with A antibodies derived from immunization with synthetic aggregates.
• The Company believes that the observed selectivity of PMN267 for misfolded TDP-43 and avoidance of normal TDP-43 has the potential to allow for inhibition of disease without compromising essential TDP-43 function.

Industry Context

The document highlights the competitive landscape in the neurodegenerative disease space, noting the presence of both large pharmaceutical companies and smaller biotechnology firms. It also emphasizes the high failure rate in Alzheimer's drug development, underscoring the need for novel approaches like ProMIS's.

Comparison to Industry Standards

• The document compares PMN310 to other anti-amyloid antibodies like aducanumab, lecanemab, and donanemab, highlighting PMN310's selectivity for oligomers and reduced binding to plaque.
• The document notes that antibodies binding to A monomers have not been efficacious in AD, suggesting that high selectivity for low abundance toxic AO is desirable.
• The document mentions that treatment with aducanumab, lecanemab, and donanemab was associated with ARIA-E and ARIA-H, which are correlated with binding to insoluble deposits of A in the vasculature and plaque.
• The document states that PMN310 avoided monomer target distraction, with the smallest percent inhibition of binding to brain oligomers when compared to other A-directed antibodies.

Related Party Transactions

• The company entered into a collaborative research agreement with the University of British Columbia (UBC) and the Vancouver Coastal Health Authority, with the company's Chief Scientific Officer as principal investigator at the UBC.
• The company entered into transactions with Title 19 Promis, a related party that holds an equity interest in the company, including the issuance of convertible debentures and the acquisition of common shares and warrants.
• The company entered into transactions with Crocker Mountain LLC and the Jeremy M. Sclar 2012 Irrevocable Family Trust, related parties that hold an equity interest in the company, including the issuance of convertible debentures and the acquisition of common shares and warrants.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and the potential for a decline in share price due to the company's financial situation.
• Employees may be affected by potential delays or reductions in research and development programs due to funding constraints.
• Patients may benefit from the development of new therapies for neurodegenerative diseases, but the success of these therapies is not guaranteed.
• Strategic partners may be affected by the company's ability to secure additional funding and advance its product candidates.

Next Steps

• Complete the Phase 1a clinical study with PMN310 in Healthy Volunteers.
• Prepare for the Phase 1b clinical study with PMN310 in Alzheimer's patients.
• Conduct further preclinical studies to support pipeline candidates.

Key Dates

Keywords

Alzheimer's disease, Amyotrophic lateral sclerosis, Multiple system atrophy, Antibody therapies, Therapeutic vaccines, Neurodegenerative diseases, Misfolded proteins, PMN310, PMN267, PMN442, Clinical trials, Intellectual property, Biotechnology, Drug development